Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis.

ABSTRACT:

Background

To date, no studies have described randomized controlled trials (RCTs) evaluating the effectiveness and safety of various biological agents used in induction therapy for lupus nephritis.

Objectives

We designed this study to assess the relative efficacy and safety of some of these biological agents in patients with lupus nephritis.

Method

We collected data from RCTs that examined the efficacy and safety of any biological agents for lupus nephritis and then used these data to complete a Bayesian network meta-analysis to combine the direct and indirect evidence from these studies.

Results

We identified nine RCTs evaluating rituximab, abatacept, belimumab, anifrolumab, obinutuzumab, ocrelizumab, and low-dose interleukin-2 (IL-2) across 1,480 patients. Lo

SUBMITTER: Lee YH 

PROVIDER: S-EPMC9843543 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature